Mucopolysaccharidosis Therapeutics – Pipeline Assessment and Market Forecasts to 2017

April 28, 2011 - PRLog -- GlobalData’s analysis revealed that the global Mucopolysaccharidosis (MPS) market was worth $0.65 billion in 2010. It is forecast to grow at a Compound Annual Growth Rate (CAGR) of 9.6% for the next seven years, to reach $1.24 billion by 2017. This is primarily attributed to the increase in the prevalence of the disease and pipeline molecules targeting the MPS subtypes where there were no approved treatment options available. A weak clinical pipeline coupled with high unmet need in the MPS therapeutics market will lead to the steady growth in the market.

GlobalData’s analysis of the current competitive landscape for MPS drugs revealed that the competition is weak. Although MPS is a rare disease and a niche indication, there are only three FDA (Food and Drug Administration) approved drugs on the market and target only specific types of MPS: Aldurazyme (laronidase) for MPS I, Elaprase (idursulfase) for MPS II and Naglazyme (galsulfase) for MPS VI. No drug therapy is available for MPS III, IV and VII. All of these therapies are enzyme replacement therapies, which replace the deficient enzyme and target the underlying cause of the disease, but do not cure the disease. These therapies halt the progression of the disease as long as the therapy is ongoing. Stem cell transplant is another treatment option currently used only for MPS I, VI and VII. Based on the availability of limited treatment options for specific types of MPS, the current competition in the MPS therapeutic market is characterized as weak. The key companies operating in the MPS market are BioMarin Pharmaceuticals Inc and Genzyme (Sanofi-Aventis) and Shire Plc. There are no approved drugs or therapies for the other subtypes of MPS.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages....


The global MPS therapeutics market is attractive, with high unmet need. This unmet need in the market is 68%, valued at $0.44 billion. This is due to limited treatment options, high cost of therapy, poor diagnosis, moderate safety and efficacy profile of the marketed drugs and no approved drug treatment for MPS III, IV and VII. The MPS market offers significant opportunities for newer cost effective treatment options and therapies targeting other MPS subtypes.

GlobalData, the industry analysis specialist, has released its new report, “Mucopolysaccharidosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global mucopolysaccharidosis market. The report identifies the key trends shaping and driving the global mucopolysaccharidosis market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global mucopolysaccharidosis sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Muco...

Visit our report store: http://www.globaldata.com

For more details contact:
pressreleases@globaldata.com            
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage including oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries.